Medical imaging is among the most important innovations of our times, but modern healthcare asks more from it than ever before.
Misclassification rates resulting in over- and under-diagnosis are too high in cardiology and oncology, driving costs. This uncertainty makes it even harder to measure change reliably, one of the requirements for the use of imaging in personalized medicine. Successive rounds of hardware innovations produce ever bigger data sets, ever richer – but which challenge unaided interpretation.
What would it look like to better align medical imaging to the goals of outcome-based reimbursement models needed by Accountable Care Organizations? To scale well to address the needs of integrated delivery networks?
Elucid Bioimaging addresses these needs using its patented, multi-modality, Computer-Aided Phenotyping (CAP) Platform, first in cardiology and oncology, with potential beyond.
- Publication: Statistical Issues in Testing Conformance with the Quantitative Imaging Biomarker Alliance (QIBA) Profile Claims, Academic Radiology, April 2016
- Issued patent: Classification of Biological Tissue by Multi-Mode Data Registration, Segmentation, and Characterization. US Patent 9,235,887, issued January 12, 2016 (file date January 2013)
- Citation: Antoniadis et al., Foretelling plaque disruption: Is the journey to Ithaca reaching destination? Atherosclerosis 244 (January 2016) 147-148
- Publication: Inter-Method Performance Study of Tumor Volumetry Assessment on Computed Tomography Test-Retest Data, Academic Radiology, November 2015
- Publication: Identification of High-Risk Plaques by MRI and Fluorescence Imaging in a Rabbit Model of Atherothrombosis, PLOS One, October 2015
- Publication: Inter-Method Performance Study of Tumor Volumetry Assessment on Computed Tomography Test-Retest Data, Academic Radiology,September 2015
- Read More News...